title: Behavioural and hypothalamic molecular effects of the anti-cancer agent cisplatin in the rat: A model of chemotherapy-related malaise?
abstract: Many cancer patients receiving chemotherapy experience fatigue, disturbed circadian rhythms, anorexia and a variety of dyspeptic symptoms including nausea. There is no animal model for this 'chemotherapy-related malaise' so we investigated the behavioural and molecular effects of a potent chemotherapeutic agent, cisplatin (CP, 6 mg/kg, i.p.) in rats. Dark-phase horizontal locomotor activity declined post-CP reaching a nadir on day 3 (P < 0.001), before recovering after 7 days. CP's effect was most marked in the late part (05.00-07.00) of the dark-phase. Food intake reached a nadir (P > 0.001) at 2 days, coincident with an increase in gastric contents (cisplatin 9.04+/-0.8 vs. saline 2.32+/-0.3 g; P < 0.001). No changes occurred in hypothalamic mRNA expression for AGRP, NPY, HCRT, CRH, IL-1, IL-6, TNFalpha, ABCG1, SLC6A4, PPIA and HPRT mRNA but tryptophan hydroxylase (TPH) mRNA was decreased (47%, P < 0.05) at day 21 post-CP. This shows that despite marked behavioural effects of cisplatin, only a discrete change (TPH) was found in hypothalamic mRNA expression and that occurred when the animals' behaviour had recovered. Findings are discussed in relation to the neuropharmacology of chemotherapy-induced malaise.
authors.affiliation: Division of Basic Medical Sciences, St. George's University of London, London, SWl7 ORE, Harlow, Essex CMl9 5AW, UK.
authors.forename: N M
authors.initials: NM
authors.lastname: Malik
authors.forename: G B T
authors.initials: GB
authors.lastname: Moore
authors.forename: G
authors.initials: G
authors.lastname: Smith
authors.forename: Y-L
authors.initials: YL
authors.lastname: Liu
authors.forename: G J
authors.initials: GJ
authors.lastname: Sanger
authors.forename: P L R
authors.initials: PL
authors.lastname: Andrews
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects; D002945:Cisplatin / Q000009:adverse effects* / Q000494:pharmacology*; D004195:Disease Models, Animal; D004326:Drinking / Q000187:drug effects; D004435:Eating / Q000187:drug effects; D005766:Gastrointestinal Contents / Q000187:drug effects; D007031:Hypothalamus / Q000187:drug effects* / Q000378:metabolism*; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000970:Antineoplastic Agents; D012333:RNA, Messenger; D002945:Cisplatin